Boucoiran Isabelle, Roy Melissa, Poliquin Vanessa, Elwood Chelsea, Sheehan Nancy L, Thibaudeau Rosie, Ferreira Ema, Autmizguine Julie, Kakkar Fatima, Boucher Marc, Money Deborah, Tulloch Karen
Department of Obstetrics and Gynecology, Division of Maternofetal Medicine, 5622Université de Montréal, Montreal, Canada.
Department of Social and Preventive Medicine, 5622École de Santé Publique de Université de Montréal, Montreal, QC, Canada.
Int J STD AIDS. 2021 Jun;32(7):654-661. doi: 10.1177/0956462420984694. Epub 2021 Feb 20.
We wished to evaluate the efficacy, safety, and acceptability of cabergoline for lactation inhibition in women who live with HIV. In this multicenter prospective observational study, cabergoline was offered as a single oral dose of 1 mg within the first 48 h postpartum. Women were recruited if they delivered a live infant after 35 weeks of gestational age. Participants filled out a questionnaire regarding symptoms of lactation and cabergoline adverse effects on day 2 and day 14 postpartum. On day 14, they also completed a questionnaire about their satisfaction with cabergoline treatment. Prolactin serum level was measured on both visits. Among 68 participants, all but one received cabergoline. The overall effectiveness defined by partial or complete success at day 14 was 98.3% (confidence intervals: 89.5-99.9). At day 14, 67.4% of women who received cabergoline had prolactin serum levels <25 mcg/L (threshold necessary for galactopoiesis). Mild nonspecific adverse effects were experienced by 24 (29.9%) women on day 2 and 24 (41.4%) on day 14, and lasted 48 h or less. Overall, 96% of women were satisfied with cabergoline's ability to prevent postpartum lactation symptoms. In conclusion, cabergoline is an effective, well-accepted, and well-tolerated medication for lactation inhibition in WLWH.
我们希望评估卡麦角林对感染艾滋病毒女性抑制泌乳的疗效、安全性和可接受性。在这项多中心前瞻性观察研究中，在产后48小时内给予卡麦角林单次口服剂量1毫克。如果女性在孕35周后分娩活婴，则招募她们。参与者在产后第2天和第14天填写一份关于泌乳症状和卡麦角林不良反应的问卷。在第14天，他们还完成了一份关于对卡麦角林治疗满意度的问卷。两次就诊时均测量血清催乳素水平。在68名参与者中，除一人外均接受了卡麦角林治疗。以第14天部分或完全成功定义的总体有效率为98.3%（置信区间：89.5-99.9）。在第14天，接受卡麦角林治疗的女性中有67.4%的血清催乳素水平<25微克/升（产乳所需阈值）。24名（29.9%）女性在第2天出现轻度非特异性不良反应，24名（41.4%）在第14天出现，持续时间为48小时或更短。总体而言，96%的女性对卡麦角林预防产后泌乳症状的能力感到满意。总之，卡麦角林是一种有效、易于接受且耐受性良好的用于感染艾滋病毒女性抑制泌乳的药物。
